Montag & Caldwell LLC decreased its holdings in Becton Dickinson and Co (NYSE:BDX) by 22.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 265,595 shares of the medical instruments supplier’s stock after selling 76,121 shares during the quarter. Becton Dickinson and accounts for approximately 3.4% of Montag & Caldwell LLC’s investment portfolio, making the stock its 11th biggest holding. Montag & Caldwell LLC owned 0.10% of Becton Dickinson and worth $66,933,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Harvest Group Wealth Management LLC purchased a new stake in shares of Becton Dickinson and during the 1st quarter worth approximately $25,000. TRUE Private Wealth Advisors purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth approximately $25,000. Hexavest Inc. purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth approximately $28,000. Lipe & Dalton purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth approximately $28,000. Finally, Pinnacle Financial Partners Inc. purchased a new stake in shares of Becton Dickinson and during the 1st quarter worth approximately $29,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.
BDX has been the subject of several research analyst reports. Raymond James raised their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research note on Friday, June 28th. UBS Group decreased their price target on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. Barclays upgraded shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target for the company in a research note on Monday, May 13th. Morgan Stanley raised their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 16th. Finally, Zacks Investment Research upgraded shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Monday, May 20th. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $264.27.
Becton Dickinson and stock traded up $1.54 during mid-day trading on Thursday, reaching $246.25. The company’s stock had a trading volume of 455,093 shares, compared to its average volume of 1,059,462. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The firm has a market cap of $66.49 billion, a P/E ratio of 22.37, a P/E/G ratio of 1.81 and a beta of 1.11. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. The stock has a fifty day moving average of $251.98.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.37 billion. During the same period in the previous year, the business earned $2.91 EPS. Becton Dickinson and’s revenue was up 1.7% compared to the same quarter last year. Equities analysts expect that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a $0.77 dividend. The ex-dividend date is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.25%. Becton Dickinson and’s dividend payout ratio is 27.97%.
In related news, insider James C. Lim sold 1,929 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $252.01, for a total value of $486,127.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Patrick Kaltenbach sold 275 shares of Becton Dickinson and stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $235.00, for a total transaction of $64,625.00. Following the completion of the transaction, the executive vice president now owns 16,482 shares of the company’s stock, valued at $3,873,270. The disclosure for this sale can be found here. Insiders sold a total of 24,529 shares of company stock valued at $5,836,116 over the last quarter. 0.12% of the stock is owned by company insiders.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: Put Option Volume
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.